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Abstract
Purpose—Glioblastoma is a devastating, incurable disease with few known prognostic factors.
Here we present the first genome-wide survival and validation study for glioblastoma.
Methods—Cox regressions for survival with 314,635 inherited autosomal single nucleotide
polymorphisms (SNPs) among 315 San Francisco Adult Glioma Study patients for discovery and
three independent validation datasets (87 Mayo Clinic, 232 GliomaSE and 115 The Cancer
Genome Atlas patients) were used to identify SNPs associated with overall survival for Caucasian
glioblastoma patients treated with the current standard of care, resection, radiation and
temozolomide (total n=749). Tumor expression of the gene that contained the identified prognostic
SNP was examined in three separate datasets (total n=619). Genotype imputation was used to
estimate hazard ratios (HRs) for SNPs that had not been directly genotyped.
Results—From the discovery and validation analyses, we identified a variant in SSBP2 (single-
stranded DNA-binding protein 2) on 5q14.1 associated with overall survival in combined analyses
(hazard ratio (HR) = 1.64; P = 1.3X10−6). Expression of SSBP2 in tumors from three independent
datasets also was significantly related to patient survival (P = 5.3 X 10−4). Using genotype
imputation, the SSBP2 SNP rs17296479 had the strongest statistically significant genome-wide
association with poorer overall patient survival (HR = 1.79; 95% CI: 1.45–2.22; P = 1.0 X 10−7).
Conclusion—The minor allele of SSBP2 SNP rs17296479 and the increased tumor expression
of SSBP2 were statistically significantly associated with poorer overall survival among
glioblastoma patients. With further confirmation, previously unrecognized inherited variations
influencing survival may warrant inclusion in clinical trials to improve randomization.
Unaccounted for genetic influence on survival could produce unwanted bias in such studies.
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Glioblastoma is a rapidly fatal form of primary brain cancer with few known prognostic
factors. Major challenges of achieving complete patient follow-up, treatment heterogeneity
and changing patterns of patient care over time have limited the feasibility of genome-wide
cancer survival discovery with very few such studies published for any cancer site (1) and
none thus far for glioblastoma. Moreover, candidate gene studies for glioblastoma survival
have provided equivocal results (2–9) possibly due to the factors above or to inadequate
gene coverage. In order to minimize these challenges, we focused this first genome-wide
discovery and validation study for glioblastoma patient survival on carefully selected




Informed consent was obtained from each subject. The subject recruitment and studies were
conducted after approval was obtained from the investigational review boards at each
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participating site in accordance with assurances filed with and approved by the U.S.
Department of Health and Human Services. (10, 11)
Discovery Study—Details of subject ascertainment for the San Francisco Adult Glioma
Study (AGS) have been previously described. (10, 12, 13) The 315 glioblastoma patients in
the present study are the subset who had received current standard-of-care treatment
(resection, radiation and temozolomide) of the 525 glioblastoma patients whose results were
used in the genome-wide association study reported by Wrensch et al. (10) after stringent
sample quality control filtering. Among these patients, tumor characteristics (IDH1 (n=173)
and TP53 (n=151) mutation status and EGFR copy number (n=173)) were available from
ongoing studies. (14–16)
Validation Study—The Mayo Clinic study included 87 glioblastoma patients newly
diagnosed between 2005 and 2008. Most cases were identified within 24 hours of diagnosis;
some were initially diagnosed elsewhere and later had their diagnosis verified at the Mayo
Clinic. Pathologic diagnosis was confirmed by review of the primary surgical material for
all cases by two Mayo Clinic neuropathologists based on surgically resected material.
The GliomaSE study included glioblastoma patients enrolled in a case-control study
conducted at medical centers in the Southeast and diagnosed with a primary (e.g. non-
recurrent) glioma between 2005 and 2010. (11) Patients were enrolled a median of 1 month
following glioblastoma diagnosis (and a maximum of 4 months according to study protocol).
The glioblastoma diagnosis was based on diagnostic pathology reports available for all
patients in the study.
The TCGA dataset was downloaded from the Cancer Genome Atlas (TCGA; http://
cancergenome.nih.gov/(17)). At the time of data retrieval from TCGA, alignment of sample
identifiers yielded 181 glioblastoma patients with both genotype and clinical data, 115 of
whom had resection, radiation and temozolomide treatment. The subject IDs of these 115
TCGA patients are listed in Supplementary Table 1.
Genotyping
Genotyping for the AGS discovery subjects was conducted by deCODE Genetics using
Illumina’s HumanCNV370-duo BeadChip as previously described (10). After excluding
SNPs with p < 10−5 for Hardy-Weinberg equilibrium in the AGS control samples (AGS
participants that did not have glioma), or minor allele frequency < 5%, or missing
genotyping data > 5% in the case groups, there were 314,635 autosomal SNPs to consider in
the survival tests. Genotyping for the Mayo Clinic study subjects was performed using
Illumina 610Quad SNP arrays as previously described (10). Genotyping for the GliomaSE
study subjects was performed using the Illumina Goldengate assay as previously described.
(10) Genotyping for the TCGA study subjects was performed using Illumina 550 platform.
(17)
Statistical Analysis
Supplementary Figure 1 provides an overview of the three types of analyses conducted: 1.
genome-wide constitutive discovery and validation of SNPs associated with glioblastoma
patient overall survival, 2. functional validation of survival loci (association of gene
expression in tumors with glioblastoma overall patient survival), and 3. fine mapping via
genotype imputation.
Genome-wide Survival and Validation Analyses—Due to human subject IRB
constraints, analyses on the raw genotype data were carried out separately at the AGS, Mayo
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Clinic and GliomaSE sites (TCGA data were analyzed at the AGS site). Summary statistics
were then submitted to the AGS site for combined analysis. For the AGS discovery study,
we conducted Cox proportional hazards regression models to assess the association of each
of the 314,635 SNPs with overall survival, adjusting for age (on a continuous scale) and sex.
The SNP variable used in the model is coded as a continuous count of the number of minor
alleles based on the additive genetic model. Per-allele hazard ratio (HR) and 95%
confidence interval were obtained for each SNP. Statistical significance for each SNP was
assessed with the Wald test. The same Cox proportional hazard models were used for all
ensuing analyses of the validation datasets. The genomic inflation factor based on the
genome-wide P values for the AGS discovery study was 1.04 indicating that systematic
inflation of our survival association signals due to model misspecification, undetected
genotyping error or hidden ancestry relationship was highly unlikely. The proportional
hazards assumption for validated SNPs with a four-site combined P≤10−5 was tested within
each site using the Schoenfeld residuals, and SNPs with evidence for non-proportionality
were removed from further consideration. Results for the non-proportionality test for
rs7732320 are shown in Supplementary Table 2. Heterogeneity across the four studies for
rs7732320 was assessed by Cochran’s Q statistic. (18) As no significant heterogeneity
across study sites was observed, a fixed effect model that used the inverse of the variance of
the study-specific log(HR) estimates to give weights to the contribution of each study (19),
was used to summarize results across studies. Specifically,
, where β̂i and ν̂i are the log hazard ratio estimate
and its variance for the ith study respectively.
Functional Validation of Survival Loci—To examine associations of expression of the
candidate gene, with survival, we assembled data from 619 primary glioblastoma samples
from three published studies. (20–22) The Lee et al. (20) dataset described 218 glioblastoma
expression samples including 132 samples from three previously published datasets as well
as 86 new samples assembled into a single, unified dataset using Affymetrix U133A. The
Murat et al. (21) dataset contains 75 glioblastoma expression samples using the Affymetrix
U133. Normalized expression values using the standard RMA method for the Lee and Murat
datasets were downloaded from the NCBI GEO database (GSE13041 and GSE7696). The
TCGA dataset (22) has 326 primary glioblastoma expression samples using the Affymetrix
U133A expression platform. Transcriptional class labels were obtained from the TCGA
Advanced Working Group. (23) The updated labeling extends the original labeled set
presented in Verhaak et al. (22) to previously unclassified samples. In total, we obtained 74
Proneurals, 45 Neurals, 93 Mesenchymals and 91 Classicals. For each of the three
expression datasets, we carried out age and sex adjusted study specific survival analysis
employing Cox models relating continuous gene expression data to patient survival, and
then combined the study-specific HR estimates with a fixed effect model using the inverse
variance approach. (19) Within the TCGA expression dataset, we also conducted expression
subtype (Proneural, Neural, Classical and Mesenchymal) stratified survival analysis using a
Cox model with the same specification. As treatment data were either missing or incomplete
for these patients, we did not restrict the tumor gene expression analyses to patients with the
current standard of care.
Fine Mapping via Imputation—Using MACH (24) and data from release 22 Phase II
CEU HapMap data (MACH v 1.0.16) we imputed SNPs separately within each of the three
studies with sufficient tagging SNPs (AGS, Mayo and TCGA). MACH implements a
Markov Chain based algorithm to infer possible pairs of haplotypes for each individual’s
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genotypes (including untyped genotypes). We ran MACH with the default parameter values
with the number of iterations of the Markov Chain set to 50 and the “greedy” option turned
on. We then carried out study-specific Cox survival analysis using expected allele counts as
the predictor for a total of 159 SNPs, whose variance ratios were larger than 0.5 for all three
studies in order to exclude SNPs with poor quality imputed genotypes. Meta-analysis of the
imputed data was performed in the same way as described above. To obtain survival signals
independent of the most significant (imputed) SNP in the region, we included its expected
counts in the Cox model as an additional covariate, along with the other covariates such as
age and sex. All analyses were carried out using the R statistical package.
RESULTS
Patient characteristics (age, sex and median survival) for the four datasets (AGS, the Mayo
Clinic, GliomaSE and TCGA) are described in Table 1. The majority of the observed
survival Cox regression P values for 314,635 SNPs from the AGS discovery dataset
conformed to the identity line in the Q-Q plot, whereas 90 SNPs showed significant
deviation from expectation at P = 10−4 (Supplementary Figure 2). We submitted these 90
SNPs for validation in Mayo Clinic patients of which 78 passed quality control. Ten of these
SNPs had P < 10−5 in the combined analysis using a fixed-effect model. (25) Examination of
these 10 SNPs in two additional patient groups, GliomaSE and TCGA patients, yielded one
SNP, rs7732320, that had discovery and validation combined P < 10−5 for survival and had
proportionality of hazards in all four datasets (Table 2 and Supplementary Table 3). The
associations of this SNP with patient survival were in the same direction across the studies
and had a combined validation P = 0.008 and a combined discovery-validation P =
1.3X10−6. There was no evidence of heterogeneity of the HR estimates across the four
studies (Table 2). Effect modification by age at diagnosis for rs7732320 was evaluated in the
AGS discovery data by the significance of the interaction term between age at diagnosis and
the SNP; no statistical significant interaction was detected. In the AGS discovery data, the
median survival time for the three groups of patients with 0, 1, and 2 adverse alleles of
rs7732320 were 17.8, 13.4 and 10.6 months respectively.
Rs7732320 is located in the intronic region of SSBP2; we therefore investigated whether
patient survival was associated with the transcript levels of SSBP2 among 619 patients in
three publically available glioblastoma gene expression datasets (Lee et al., (20) Murat et al.,
(21) and TCGA (22);see Methods and Supplementary Figure 1). We observed a strong and
significant association of SSBP2 expression with poorer overall survival (HR = 1.22; 95%
CI: 1.09 – 1.36; P = 5.3 X 10−4) and the association was consistent across the three
expression datasets (Table 3). No effect modification by age at diagnosis was found for the
association of SSBP2 tumor expression with survival in any of the three expression datasets.
Additionally, among TCGA glioblastoma patients, the HR for patient survival associated
with tumor SSBP2 expression was highest and statistically significant only among patients
with the previously described (22) proneural signature (HR = 1.44; 95%CI: 1.10 – 1.89; P =
0.007) (Table 3). Consistent with this finding, we found that proneural glioblastoma patients
expressed the lowest amount of SSBP2 compared to the other subtypes (Wilcoxon P =
2.16X10−12; Figure 1A). Intriguingly, even though the overall survival for patients of the
proneural subtype was not significantly different from the other gene expression subtypes
(log rank P = 0.21; Figure 1B), significant survival differences were observed for the
proneural SSBP2-negative patients (Figure 1C), arbitrarily defined as the subset of patients
with lower than 25 percentile of SSBP2 expression in the proneural group. We observed
significantly better survival for proneural SSBP2-negative patients (median survival time:
28.8 months) than proneural SSBP2-positive patients (median survival of time: 12.4 months)
and all other non-proneural glioblastoma patients (median survival time: 13.8 months).
Proneural SSBP2-negative status remained a significant prognostic factor for longer survival
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(Cox P = 9.7X10−3) in Cox multivariate analysis after adjusting for patient age at diagnosis
and sex.
The proneural expression subtype has recently been linked to a subset of tumors exhibiting a
glioma-CpG island methylator phenotype (G-CIMP)(26). To understand the relationship
between SSBP2 and the G-CIMP signature, we compared the SSBP2 genotype and tumor
expression in the set of TCGA glioblastoma samples with available G-CIMP status. Of the
241 TCGA samples with concomitant tumor expression and G-CIMP information, 24 were
G-CIMP positive and they expressed a much lower level of SSBP2 than the 217 G-CIMP
negative tumors (Wilcoxon P = 3.54X10−4). Of the 151 TCGA samples with attendant
SSBP2 genotype and G-CIMP information, 2 out of the 16 (12.5%) G-CIMP positive
glioblastoma patients belonged to the group with at least one copy of the adverse allele T, in
contrast to a much higher proportion (28.4%, 38 out of 135) in the G-CIMP negative
glioblastomas. Because of small sample sizes, validating the relationship between SSBP2
genotype, expression and G-CIMP status will require further studies.
Interestingly, IDH1 mutation status was not found to be associated with the SSBP2 genotype
in either of the AGS and TCGA datasets, nor was it linked to SSBP2 tumor expression in the
TCGA dataset. For TP53 mutation, we detected an increased frequency of the risk allele T
of SSBP2 in TP53 mutated glioblastoma patients (OR = 2.35; 95% CI = 1.06–5.19; P =
0.03) in the TCGA dataset. However, this association was not found in the AGS dataset.
Next, in order to perform a multivariate analysis incorporating both patient genotypes and
tumor markers that are related to survival in glioblastoma patients, we used the AGS dataset,
for whom 143 of the 315 patients with standard-of-care treatment had data on TP53 and
IDH1 mutation status, and EFGR amplification. Unfortunately only 35 of the 115 TCGA
patients with standard-of-care treatment had both IDH1 and TP53 mutation data. In a Cox
multivariate regression including age, sex, IDH1 mutation status, EGFR copy number, TP53
mutation and SSBP2 rs7732320 genotype, SSBP2 genotype remained an independent
predictor of poorer survival (HR=1.99; 95%CI: 1.32–3.00, P=0.001, n=143)
Taken together, the findings above present a consistent connection by showing that both the
adverse SSBP2 inherited variant and increased SSBP2 expression in tumors are associated
with shorter survival time in glioblastoma patients and that the relationship is most evident
among patients with the proneural expression signature. A test for the statistical interaction
between the SSBP2 SNP rs773232 and its tumor expression was performed in the TCGA
dataset by inclusion of the cross-product term in the Cox model and assessed by use of the
likelihood ratio test. No statistical significant interaction effect (P=0.66) was observed.
To further localize the association with survival in the 5q14.1 region around rs7732320, we
imputed non-genotyped SNPs in the entire genomic locus of SSBP2 with a 100kb extension
at its 3′ end from 80,680,000 – 80,980,000 on chromosome 5. The Hapmap II CEU dataset
(27) contained 217 SNPs in this region (the AGS dataset had 31 SNPs). Out of the 186 (217
minus 31) imputed SNPs, 159 had good imputation quality for AGS, Mayo, and TCGA.
Meta-analysis using a fixed effect model to combine study-specific HR estimates from age-
gender adjusted Cox models shows a genome-wide statistically significant association of
patient survival with the SNP rs17296479 (P = 1.0 X 10−7; see Figure 2 and Supplementary
Table 4), which is located ~8kb centromeric of rs7732320. Two SNPs, rs12187089 and
rs11738172, located between these two markers, also displayed strong associations with
patient survival, with P = 1.2 X 10−7 and 2.3 X 10−7 respectively. These four SNPs are
highly linked with each other (r2 > 0.8). The smallest combined nominal P value from
multivariate Cox models of patient survival with the remaining SNPs adjusting for
rs17296479 genotype was 0.061, suggesting that there were no residual independent survival
signals remaining.
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Major strengths of this study include: 1. a large group of glioblastoma patients in the
discovery study (AGS) with initial standard of care treatment of resection, radiation, and
temozolomide; 2. three independent validation studies restricted to patients also treated with
standard of care; 3. direct functional analysis of tumor gene expression at discovered loci at
different levels; and 4. imputation to localize the SNPs most strongly associated with patient
survival. Limitations of this study include the lack of detailed temozolomide dosing or
timing information, and the fact that subsequent treatments at patient relapse are not
included as part of the analysis. Another limitation is that tumor expression data was not
available for most of the patients for whom constitutive genotyping data was available, but
TCGA data did provide one group of patients with both tumor expression and constitutive
genotyping. Recently, Colman et al. (28) found an approximately 3-fold hazard ratio for
overall survival for glioblastoma associated with a 9-gene tumor expression signature among
patients treated with temozolomide. In our analysis, we have identified a distinct subset of
proneural patients with low SSBP2 expression with a median survival time that was more
than twice as long as the other glioblastoma patients. In addition, the SSBP2 risk allele
conferred a 1.64 fold increase in rate of death. As our survival analyses are done using a
single SNP covariate, the inclusion of additional SNPs in combinations with tumor makers
may lead to improved prognostic ability. Such an undertaking is an important future
direction for research.
Despite assembling the largest sample size yet available of standard of care treated primary
glioblastoma patients with genome-wide SNPs and survival data, our study is still
exploratory with relatively small sample size compared to case-control genome-wide
studies. The observed associations between the SSBP2 SNP and glioblastoma patient overall
survival did not reach nominal genome-wide significance in the discovery study. However,
genotype imputation identified an untyped SNP (rs17296479) in SSBP2 achieving genome-
wide significance (Bonferroni corrected p=1.0*10−7 *314,635 = 0.03). Nevertheless,
preventing false positive discoveries is a pertinent issue in such a large-scale study involving
so many statistical tests. Consequently, we sought additional functional validation of the
discovered loci by assessing their tumor gene expression association with survival. We
believe these additional exercises improved our chances of deriving results that can be
replicated in future studies as well as inform future functional studies.
We report here persuasive evidence for the genotypic and transcriptional association of the
SSBP2 locus with patient survival. However, establishing the nature of the regulatory
relationship between the two awaits further in-depth experimental investigation. It is also
possible that the variant is associated the natural history of the disease; leading to
differences in time of diagnosis for carriers versus non-carriers. As yet, the variant has not
been associated with glioma risk.
Using imputation for fine mapping, we identified four linked SNPs (rs17296479,
rs12187089, rs11738172 and rs7732320), spanning ~12 kb at the 3′ end of SSBP2, that are
strongly associated with patient survival. Although all four SNPs are non-coding, their
immediate proximity to the gene and the ample evidence for epigenetic modifications within
the region supports a possible role in transcriptional regulation of SSBP2. First, the histone
methylation marker H3K4Me1 for enhancer elements has a broad peak encompassing three
of the four variants (See Supplementary Figure 3). Second, there are three un-annotated
human transcripts (AK024171, AK054959 and CR608789) located in the same region, just
downstream of SSBP2, suggestive of a transcriptionally active genomic interval. Last and
most importantly, the direct functional evidence relating the variant rs7732320 to SSBP2
expression in glioblastomas and the unequivocal associations of patient survival with SSBP2
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inherited variants and SSBP2 expression levels in tumors point to a cis effect of the
variant(s) with the disruption of the transcriptional control of SSBP2 as the likely functional
mechanism. The genotyped and imputed variants could either tag the principal association
with survival attributable to this 5q14.1 locus or they themselves could be the principal
culprits. Comprehensive resequencing efforts and further functional analysis will be required
to unambiguously identify the causal variants.
As further evidence of the biologic plausibility of these findings, SSBP2 has been reported
to be involved in the maintenance of genome stability (29) and has been implicated in
transcriptional signatures in several cancers including leukemia, (30) pancreatic cancer, (31)
oligodendroglial tumors, (32) and esophageal squamous cell carcinoma. (29) A direct
confirmation of the link between SSBP2 and survival in brain cancer is further proffered by
Shaw et al., (32) in which the expression of SSBP2 was shown to be associated with
response to chemotherapy in patients with oligodendroglial tumors. Evidence that the
genotypic association of SSBP2 with patient survival appears to be independent of tumor
IDH1 mutation status and strongest among patients with a proneural/G-CIMP expression
signature suggests SSBP2 may contribute to glioblastoma pathogenesis.
With further confirmation, these previously unrecognized inherited variations influencing
survival may warrant inclusion in clinical trials to improve randomization and validate new
therapeutic approaches. The genes identified here by SNP tags may represent potential
targets for developing new drug therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
Glioblastoma is the most fatal form of primary brain cancer and only a few prognostic
factors, age, initial Karnofsky performance status and some treatments, are known.
Reliable genetic prognostic markers are still not well established. We present the first
genome-wide survival and validation study for glioblastoma patients treated with the
current standard of care, resection, radiation and temozolomide. Using Cox regressions
for genome-wide survival analysis, followed by functional validation in tumor expression
and genotype imputation, we identified a variant in SSBP2 (single-stranded DNA-
binding protein 2) and the tumor expression of SSBP2 to be significantly associated with
patient survival. Identification and characterization of the role of genetic variation in
predicting glioblastoma patient survival may help optimize clinical trial study design and
individualize patient treatment plans.
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(A) Boxplots of SSBP2 tumor expression by previously assigned TCGA expression groups
in 303 glioblastomas: C, classical; M, mesenchymal; N, neural; and P, proneural. (B)
Kaplan-Meier survival curves for the four TCGA expression groups. (C) Kaplan-Meier
survival curves based on SSBP2 expression and TCGA expression groups. The “Proneural
SSBP2-” group is designated as the subset of 20 patients with lower than 25 percentile
expression of SSBP2 expression in the proneural group.
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Association of genetic variants near SSBP2 with survival using data from uniformly treated
glioblastoma patients. We used data from the San Francisco Adult Glioma Study, the Mayo
Clinic and The Cancer Genome Atlas studies for imputation. Evidence for association at
each SNP, measured as the combined -log10 P-value, is represented along the y-axis. The x-
axis represents the placement of each SNP on chromosome 5 in genome build 36. Results
for directly genotyped SNPs are colored in blue, and imputed SNPs in red. Association
results are superimposed on a black line that summarizes the local recombination rate map.
The upper panel indicates known RefSeq and mRNA coding sequences in the region.
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